UCB To Acquire Candid Therapeutics For Up To $2.2 Billion
By Amit Chowdhry ● May 3, 2026
UCB, a global biopharmaceutical company, has signed a definitive agreement to acquire Candid Therapeutics, a privately held clinical-stage biotechnology company developing novel T-cell engagers for the treatment of autoimmune and inflammatory diseases, for up to $2.2 billion. The deal comprises $2 billion in upfront payments and up to $200 million in potential future milestone payments, and is expected to close by the end of the second quarter or early third quarter of 2026, pending antitrust clearance and other customary conditions.